Company · founded 2001
APT Therapeutics (United States)
St Louis, United States · apt-therapeutics.com
- Citations, last 5 years
- 0
- Works, last 5 years
- 27
- h-index
- 18
- Scientists listed
- 1
- Grants since 2016
- 32
Grants received
2024–2025 · research · R43
Discovering targeted modulator of microglial activity as a candidate treatment for FTD and related dementias.
Martin Jacko · APT Therapeutics (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R44
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer
Eric J Brown · APT Therapeutics (United States) · funded by National Institutes of Health
2023–2025 · research · R41
Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma
Esther M Alegria · APT Therapeutics (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer
Eric J Brown · APT Therapeutics (United States) · funded by National Institutes of Health
2023–2026 · research · R44
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2023–2027 · research · R44
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2022–2023 · research · R43
Intestinal Drug Transporters in Veterinary Animals
Claire Brett · APT Therapeutics (United States) · funded by U.S. Food and Drug Administration
2021–2023 · research · R43
Peripherally Acting Analgesic for Osteoarthritis Pain
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2020–2021 · research · R44
Phosphosulindac for dry eye
Basil Rigas · APT Therapeutics (United States) · funded by National Institutes of Health
2020–2023 · research · R43
Drug Transporters in Farm Animals
Claire Brett · APT Therapeutics (United States) · funded by U.S. Food and Drug Administration
2020–2024 · research · R44
Phosphosulindac for dry eye
Despina Komninou · APT Therapeutics (United States) · funded by National Institutes of Health
2020–2025 · research · R44
Phosphosulindac for dry eye
Despina Komninou · APT Therapeutics (United States) · funded by National Institutes of Health
2020–2023 · research · R43
Anti-inflammatory and Anti-diabetic Therapy for Metabolic Syndrome
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2019–2022 · research · R43
A Transporter Platform Technology For Discovery of Drugs to Treat Autoimmune Disease
Claire Brett · APT Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Combination treatment with tPA and IL2 analog for Stroke
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2018–2021 · research · R43
Immunomodulatory Therapy for Neuropathic Pain
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2018–2021 · research · R43
Prevention of Post-MI Heart Failure with Immunomodulatory Therapy
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2018–2024 · research · R44
Immunomodulatory Therapy for Neuropathic Pain
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2018–2024 · research · R44
Immunomodulatory Therapy for Neuropathic Pain
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2018–2025 · research · R44
Immunomodulatory Therapy for Neuropathic Pain
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Development of a Pharmacoprotector for Platinum Toxicities
Claire Brett · APT Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Antithrombotic Therapy with No Bleeding Risk for PCI
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Antithrombotic Therapy with No Bleeding Risk for PCI
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · research · R43
Immunomodulatory Therapy for Diabetic Nephropathy
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Antithrombotic Therapy with No Bleeding Risk for PCI
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2016–2017 · research · R43
IL2-based Immunotherapy for Type 2 Diabetes
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Development of Transporter Targeted Platinum Drugs for Glioblastoma
Huan-Chieh Chien · APT Therapeutics (United States) · funded by National Institutes of Health
2016–2018 · research · R43
IL2-based Immunotherapy for Lupus
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health
2007–2020 · grant · SB1
Human Apyrase Therapy for Acute Ischemic Stroke
Ridong Chen · APT Therapeutics (United States) · funded by National Institutes of Health